Johnson & Johnson (NYSE:JNJ) Trading 2% Higher – Here’s Why

Shares of Johnson & Johnson (NYSE:JNJ) traded up 2% on Tuesday . The stock traded as high as $237.71 and last traded at $236.8810. 8,192,473 shares traded hands during mid-day trading, a decline of 2% from the average session volume of 8,338,312 shares. The stock had previously closed at $232.16.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson announced positive Phase 2/3 results for IMAAVY (nipocalimab-aahu) in warm autoimmune hemolytic anemia, showing statistically significant durable hemoglobin improvement and a rapid onset of effect. The data strengthen the case for a potential new rare-disease franchise with no FDA-approved treatment options. Article link
• Positive Sentiment: J&J said it is expanding U.S. availability of TECNIS PureSee IOL, broadening access to its cataract surgery lens platform and adding another incremental medtech growth driver. Article link
• Positive Sentiment: Multiple commentary pieces highlighted bullish views on JNJ, citing valuation support, strong drug profits, a “triple-A” balance sheet, and its appeal as a dividend-growth stock. These pieces likely reinforce investor confidence in the name. Article link
• Positive Sentiment: Johnson & Johnson agreed to acquire Firefly Bio for $1 billion, a move aimed at deepening its oncology pipeline and expanding into KRAS-driven cancer treatments. The deal supports longer-term growth expectations. Article link
• Neutral Sentiment: Analysts and valuation-focused articles noted that J&J has posted strong recent share-price momentum, but also that the stock still trades at a premium earnings multiple. That suggests investors are re-rating the company, though not on a single clear fundamental surprise. Article link
• Negative Sentiment: A Los Angeles jury awarded $32 million in a talc/asbestos case, reminding investors that J&J’s legal liabilities remain an ongoing risk and could pressure sentiment around the stock. Article link
• Negative Sentiment: Separate coverage of the talc litigation emphasized that the verdict is part of a broader balance between legal risk and growth, indicating the issue is still a drag on the investment case even as the company’s fundamentals improve. Article link

Analyst Ratings Changes

Several research firms have commented on JNJ. JPMorgan Chase & Co. boosted their target price on Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Raymond James Financial boosted their target price on Johnson & Johnson from $237.00 to $258.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Stifel Nicolaus boosted their target price on Johnson & Johnson from $220.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, April 15th. Bank of America boosted their target price on Johnson & Johnson from $253.00 to $254.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Finally, Argus boosted their target price on Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a report on Thursday, April 16th. Twenty equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $253.04.

Johnson & Johnson Stock Up 0.0%

The firm has a market capitalization of $574.33 billion, a P/E ratio of 27.58, a P/E/G ratio of 2.32 and a beta of 0.26. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The company has a fifty day simple moving average of $231.70 and a 200 day simple moving average of $226.87.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. The firm had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities analysts expect that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were issued a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, May 26th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.2%. Johnson & Johnson’s dividend payout ratio is currently 61.97%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of JNJ. Vanguard Group Inc. increased its position in Johnson & Johnson by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after acquiring an additional 3,731,074 shares during the last quarter. State Street Corp increased its position in Johnson & Johnson by 1.3% during the fourth quarter. State Street Corp now owns 133,869,843 shares of the company’s stock valued at $27,704,364,000 after acquiring an additional 1,663,782 shares during the last quarter. Auto Owners Insurance Co increased its position in Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after acquiring an additional 69,108,368 shares during the last quarter. Geode Capital Management LLC increased its position in Johnson & Johnson by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company’s stock valued at $11,967,947,000 after acquiring an additional 1,738,292 shares during the last quarter. Finally, Norges Bank purchased a new stake in Johnson & Johnson during the fourth quarter valued at $6,924,523,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.